IP Library Granted Patent US 9,539,233
Granted Patent B2
US 9,539,233 · App. 12/772,854 · Granted Jan 10, 2017

Gallium formulation for the treatment and prevention of infectious diseases

Inventors: Satoshi Ohtake (Milpitas, CA); Vu Truong-Le (Campbell, CA); David Lechuga-Ballesteros (San Jose, CA); Luisa Yee (Los Altos, CA); Binh Pham (Mountain View, CA); Russell Martin (Los Gatos, CA); Atul Saxena (Milpitas, CA)
Assignee: Aridis Pharmaceuticals Inc.
A61K31/28A61K9/0078A61K9/08A61K9/14A61K9/1617A61K9/1623A61K33/24A61K47/12Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,539,233
App. No.
12/772,854
Granted
Jan 10, 2017
Kind
B2
Abstract

A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans , and multidrug resistant Pseudomonas aeruginosa , using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.

Claims (4)

1. A pharmaceutical formulation that comprises a gallium (III) and citrate dry powder, wherein the powder comprises an anti-microbially effective concentration of gallium (III) and the ratio of citrate to gallium is 2:1, and wherein the mass median aerodynamic diameter (MMAD) of the powder is 3.87 μm to 5.0 μm.

2. The pharmaceutical formulation of claim 1 , wherein the formulation has a molar ratio of nitrate: gallium lower than 0.1:1.

3. The pharmaceutical formulation of claim 1 , that comprises a complexing agent selected from mannitol, maltolate, protoporphyrin IX or its derivative, siderophores of the catecholate, hydroxamate, and hydroxycarboxylate groups, bacterial hemophores, an iron chelator, or a mixture thereof.

4. A method for treating an infection comprising administering the pharmaceutical formulation of claim 1 to a subject having the infection, wherein the infection agent is selected from the group consisting of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Burkholderia cepacia, Acinetobacter baumannii, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans , multidrug resistant Pseudomonas aeruginosa, Mycobacterium tuberculosis, Staphylococcus aureus, Rhodococcus eaui , methycillin resistant Staphylococcus aureus (MRSA), Actinobacteria, Lactobacillales, Actinomycies , and Clostridium.

Assignments (2)
SECURITY INTEREST Recorded Jun 21, 2023
From: ARIDIS PHARMACEUTICALS, INC.; ARIDIS BIOPHARMACEUTICALS, LLC; ARIDIS PHARMACEUTICALS, C.V.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 064020/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2013
From: OHTAKE, SATOSHI; LECHUGA-BALLESTEROS, DAVID; TRUONG-LE, VU; YEE, LUISA; PHAM, BINH V.; MARTIN, RUSSELL; SAXENA, ATUL
To: ARIDIS PHARMACEUTICALS, INC.
Reel/Frame 029955/0330 →
Continuity (2)
Provisional Application 61175457 · May 4, 2009
Related Publication 20120128729A1 · May 24, 2012